NYSE : RDY
Dr. Reddy's Laboratories Limited — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · India
Last price 14.11 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 11.81B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 11.85B |
| Enterprise Value | 11.84B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 23, 2026 |
| Ex-Dividend Date | Jul 24, 2026 |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 833.07M |
| Shares Change (YoY) | -0.05% |
| Shares Change (QoQ) | -0.04% |
| Owned by Insiders (%) | 26.72% |
| Owned by Institutions (%) | 57.64% |
| Float | 600.06M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 40.06 |
| Forward PE | 25.94 |
| PS Ratio | 3.44 |
| Forward PS | 2.98 |
| PB Ratio | 2.92 |
| P/TBV Ratio | 4.22 |
| P/FCF Ratio | 81.26 |
| P/OCF Ratio | 36.39 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 40.56 |
| EV / Sales | 3.44 |
| EV / EBITDA | 22.80 |
| EV / EBIT | 37.76 |
| EV / FCF | 81.20 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.93 |
| Quick Ratio | 1.15 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | 1.40 |
| Debt / FCF | 5.17 |
| Interest Coverage | 6.67 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 7.34% |
| Return on Assets (ROA) | 3.37% |
| Return on Invested Capital (ROIC) | 6.17% |
| Return on Capital Employed (ROCE) | 7.16% |
| Weighted Average Cost of Capital (WACC) | 5.58% |
| Revenue Per Employee | $124,971 |
| Profits Per Employee | $10,603 |
| Employee Count | 27,527 |
| Asset Turnover | 0.59 |
| Inventory Turnover | 2.12 |
Taxes
| Measure | Value |
|---|
| Income Tax | 79.67M |
| Effective Tax Rate | 21.69% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.25 |
| 52-Week Price Change | +5.67% |
| 50-Day Moving Average | 12.54 |
| 200-Day Moving Average | 13.21 |
| Relative Strength Index (RSI) | 77.68 |
| Average Volume (20 Days) | 3,035,006 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 26.14M |
| Short Previous Month | 28.96M |
| Short % of Shares Out | 3.81% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 8.16 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 3.44B |
| Gross Profit | 1.70B |
| Operating Income | 313.55M |
| Pretax Income | 367.36M |
| Net Income | 291.88M |
| EBITDA | 519.30M |
| EBIT | 313.55M |
| Earnings Per Share (EPS) | $0.35 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 795.16M |
| Total Debt | 753.91M |
| Net Cash | 41.25M |
| Net Cash Per Share | $0.05 |
| Equity (Book Value) | 4.06B |
| Book Value Per Share | 4.83 |
| Working Capital | 1.49B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 325.56M |
| Capital Expenditures | -179.77M |
| Depreciation & Amortization | 207.78M |
| Net Borrowing | 119.27M |
| Free Cash Flow | 145.79M |
| FCF Per Share | $0.18 |
Margins
| Measure | Value |
|---|
| Gross Margin | 49.49% |
| Operating Margin | 9.11% |
| Pretax Margin | 10.68% |
| Profit Margin | 8.48% |
| EBITDA Margin | 15.10% |
| EBIT Margin | 9.11% |
| FCF Margin | 4.20% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | $0.06 |
| Dividend Yield | 0.45% |
| Dividend Growth (YoY) | -10.07% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 18.24% |
| FCF Payout Ratio | 36.87% |
| Buyback Yield | 0.05% |
| Shareholder Yield | 0.50% |
| Earnings Yield | 2.50% |
| FCF Yield | 1.23% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $14.30 |
| Price Target Difference | 0.92% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 8.78% |
| EPS Growth Forecast (3Y) | 7.44% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Nov 5, 2024 |
| Split Type | Forward |
| Split Ratio | 5:1 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 5.29 |
| Piotroski F-Score | 5 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |